Sionna Therapeutics Q2 2026 net loss $29.9M; cash $268.3M; Phase 2a and Phase 1 trials on track for summer data

Sionna Therapeutics, Inc.

Net loss of $29.9M for Q2 2026, compared to $18.1M in Q2 2025.
R&D expenses $21.9M (up from $15.4M) and G&A $10.6M (up from $6.5M) driven by pipeline advancement.
Cash and equivalents $268.3M as of June 30, 2026, expected to fund operations into 2028.
PreciSION CF Phase 2a trial of SION-719 as add-on to standard of care on track for topline data summer 2026.
Phase 1 trial of SION-451 in dual combinations with SION-2222 and SION-109 also on track for topline data summer 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.